Aeris Therapeutics, LLC.
Aeris Therapeutics is engaged in the development and commercialization of novel therapies for patients with emphysema and other lung diseases.
Aeris Therapeutics' lead product is the AeriSeal® System. It is intended to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema.
Emphysema affects approximately 4 million patients in the United States and as many as 60 million patients worldwide.